Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer

被引：0
|
作者：
Taniguchi, H. [1 ]
Hasegawa, H. [2 ]
Masuishi, T. [1 ]
Narita, Y. [1 ]
Komori, A. [1 ]
Kadowaki, S. [1 ]
Ura, T. [3 ]
Muro, K. [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[2] Osaka Natl Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[3] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-232
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Serum HER2 levels determined by two methods in patients with metastatic breast cancer
    Hayashi, Naoki
    Nakamura, Seigo
    Tokuda, Yasuharu
    Yagata, Hiroshi
    Yoshida, Atsushi
    Ota, Hidekazu
    Hortobagyi, Gabriel N.
    Cristofanilli, Massimo
    Ueno, Naoto T.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (01) : 55 - 62
  • [22] Serum HER2 levels determined by two methods in patients with metastatic breast cancer
    Naoki Hayashi
    Seigo Nakamura
    Yasuharu Tokuda
    Hiroshi Yagata
    Atsushi Yoshida
    Hidekazu Ota
    Gabriel N. Hortobagyi
    Massimo Cristofanilli
    Naoto T. Ueno
    International Journal of Clinical Oncology, 2012, 17 : 55 - 62
  • [23] Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
    Takeshi Yamada
    Yoshiyuki Yamamoto
    Toshikazu Moriwaki
    Ichisnosuke Hyodo
    Journal of Gastroenterology, 2016, 51 : 506 - 507
  • [24] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [25] Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
    Zhang, Pengyu
    Xiao, Jun
    Ruan, Yingxin
    Zhang, Zhenzhen
    Zhang, Xuejun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4667 - 4675
  • [26] Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
    Yamada, Takeshi
    Yamamoto, Yoshiyuki
    Moriwaki, Toshikazu
    Hyodo, Ichisnosuke
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (05) : 506 - 507
  • [27] HER2 Testing in Metastatic Colorectal Cancer: Ready for Prime Time?
    Hurwitz, Herbert Ira
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (04) : 235 - 237
  • [28] Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification
    Raghav, Kanwal P. S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 86 - 88
  • [29] Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer
    D'Angelo, Flavia
    Monnien, Franck
    Overs, Alexis
    Pem, Irvin
    Dor, Fanny
    Abad, Marine
    Felix, Sophie
    Selmani, Zohair
    Lakkis, Zaher
    Borg, Christophe
    Doussot, Alexandre
    Bibeau, Frederic
    Molimard, Chloe
    DIAGNOSTIC PATHOLOGY, 2024, 19 (01)
  • [30] Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer.
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Takahashi, Mari
    Asano, Hiromichi
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Kojima, Takashi
    Ochiai, Atsushi
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345